Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
160 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Streptococcal Pneumonia - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Streptococcal Pneumonia - Pipeline Review, H2 2016, provides an overview of the Streptococcal Pneumonia (Infectious Disease) pipeline landscape. Pneumococcal infections are caused by the Streptococcus pneumoniae (S. pneumoniae) bacterium. They can be mild or severe. Symptoms include fever, chills, sweat, aches and pains. Risk factors include serious health condition, such as HIV or diabetes that weakens their immune system, taking medication that weakens their immune system, such as chemotherapy and age. Treatment includes antibiotics. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Streptococcal Pneumonia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Streptococcal Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Streptococcal Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Streptococcal Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 6, 6, 2, 22, 10 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 1, 8 and 4 molecules, respectively. Streptococcal Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Streptococcal Pneumonia (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Streptococcal Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Streptococcal Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Streptococcal Pneumonia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Streptococcal Pneumonia (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Streptococcal Pneumonia (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Streptococcal Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 5 Streptococcal Pneumonia Overview 6 Therapeutics Development 7 Streptococcal Pneumonia - Therapeutics under Development by Companies 9 Streptococcal Pneumonia - Therapeutics under Investigation by Universities/Institutes 11 Streptococcal Pneumonia - Pipeline Products Glance 12 Streptococcal Pneumonia - Products under Development by Companies 16 Streptococcal Pneumonia - Products under Investigation by Universities/Institutes 19 Streptococcal Pneumonia - Companies Involved in Therapeutics Development 20 Streptococcal Pneumonia - Therapeutics Assessment 54 Drug Profiles 64 Streptococcal Pneumonia - Dormant Projects 136 Streptococcal Pneumonia - Discontinued Products 140 Streptococcal Pneumonia - Product Development Milestones 141 Appendix 152
List of Tables
Number of Products under Development for Streptococcal Pneumonia, H2 2016 14 Number of Products under Development for Streptococcal Pneumonia - Comparative Analysis, H2 2016 15 Number of Products under Development by Companies, H2 2016 16 Number of Products under Development by Companies, H2 2016 (Contd..1) 17 Number of Products under Investigation by Universities/Institutes, H2 2016 18 Comparative Analysis by Late Stage Development, H2 2016 19 Comparative Analysis by Clinical Stage Development, H2 2016 20 Comparative Analysis by Early Stage Development, H2 2016 21 Comparative Analysis by Unknown Stage Development, H2 2016 22 Products under Development by Companies, H2 2016 23 Products under Development by Companies, H2 2016 (Contd..1) 24 Products under Development by Companies, H2 2016 (Contd..2) 25 Products under Investigation by Universities/Institutes, H2 2016 26 Streptococcal Pneumonia - Pipeline by Abera Bioscience AB, H2 2016 27 Streptococcal Pneumonia - Pipeline by Actelion Ltd, H2 2016 28 Streptococcal Pneumonia - Pipeline by Affinivax Inc, H2 2016 29 Streptococcal Pneumonia - Pipeline by Allergan Plc, H2 2016 30 Streptococcal Pneumonia - Pipeline by Arsanis Inc, H2 2016 31 Streptococcal Pneumonia - Pipeline by AstraZeneca Plc, H2 2016 32 Streptococcal Pneumonia - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2016 33 Streptococcal Pneumonia - Pipeline by Biken Inc, H2 2016 34 Streptococcal Pneumonia - Pipeline by ContraFect Corp, H2 2016 35 Streptococcal Pneumonia - Pipeline by Crestone Inc, H2 2016 36 Streptococcal Pneumonia - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 37 Streptococcal Pneumonia - Pipeline by FluGen Inc, H2 2016 38 Streptococcal Pneumonia - Pipeline by GlaxoSmithKline Plc, H2 2016 39 Streptococcal Pneumonia - Pipeline by ImmunoBiology Ltd, H2 2016 40 Streptococcal Pneumonia - Pipeline by Indian Immunologicals Ltd, H2 2016 41 Streptococcal Pneumonia - Pipeline by Integrated BioTherapeutics Inc, H2 2016 42 Streptococcal Pneumonia - Pipeline by Lascco SA, H2 2016 43 Streptococcal Pneumonia - Pipeline by LegoChem Biosciences Inc, H2 2016 44 Streptococcal Pneumonia - Pipeline by Liquidia Technologies Inc, H2 2016 45 Streptococcal Pneumonia - Pipeline by Merck & Co Inc, H2 2016 46 Streptococcal Pneumonia - Pipeline by Mucosis BV, H2 2016 47 Streptococcal Pneumonia - Pipeline by Panacea Biotec Ltd, H2 2016 48 Streptococcal Pneumonia - Pipeline by Pfizer Inc, H2 2016 49 Streptococcal Pneumonia - Pipeline by Prometheon Pharma LLC, H2 2016 50 Streptococcal Pneumonia - Pipeline by Sanofi Pasteur SA, H2 2016 51 Streptococcal Pneumonia - Pipeline by Serum Institute of India Ltd, H2 2016 52 Streptococcal Pneumonia - Pipeline by Shionogi & Co Ltd, H2 2016 53 Streptococcal Pneumonia - Pipeline by SK Chemicals Co Ltd, H2 2016 54 Streptococcal Pneumonia - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 55 Streptococcal Pneumonia - Pipeline by Valneva SE, H2 2016 56 Streptococcal Pneumonia - Pipeline by Vaxxilon AG, H2 2016 57 Streptococcal Pneumonia - Pipeline by Virometix AG, H2 2016 58 Streptococcal Pneumonia - Pipeline by Wellstat Vaccines LLC, H2 2016 59 Streptococcal Pneumonia - Pipeline by Wockhardt Ltd, H2 2016 60 Assessment by Monotherapy Products, H2 2016 61 Assessment by Combination Products, H2 2016 62 Number of Products by Stage and Target, H2 2016 64 Number of Products by Stage and Mechanism of Action, H2 2016 66 Number of Products by Stage and Route of Administration, H2 2016 68 Number of Products by Stage and Molecule Type, H2 2016 70 Streptococcal Pneumonia - Dormant Projects, H2 2016 143 Streptococcal Pneumonia - Dormant Projects (Contd..1), H2 2016 144 Streptococcal Pneumonia - Dormant Projects (Contd..2), H2 2016 145 Streptococcal Pneumonia - Dormant Projects (Contd..3), H2 2016 146 Streptococcal Pneumonia - Discontinued Products, H2 2016 147
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.